| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, Tokyo, and Precursory Research for Embryonic Science and Technology (M.S.), Japan Science and Technology Corporation, Kawaguchi, Japan.
Correspondence to Dr Masataka Sata, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail msata-circ{at}umin.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and Results We tested the potential involvement of p53-mediated molecular signaling in lesion formation using a mouse model of vascular injury that may resemble balloon angioplasty. A large wire was inserted into the femoral artery of p53+/+ and p53-/- mice. There was no significant difference in the occurrence of rapid-onset apoptosis, that is, 4 hours after injury. At 2 weeks, the number of proliferating cells in the lesion of p53-/- mice was significantly higher than that observed in p53+/+ mice. The frequency of apoptotic cells was significantly lower in p53-/- mice than in p53+/+ mice. At 4 weeks, the neointimal hyperplasia of p53-/- mice was greater than that of p53+/+ mice. There was no significant difference in the frequency of apoptosis in the lesions.
Conclusions These results indicate a crucial role of p53 in pathological vascular remodeling after mechanical injury and provide the basis for the development of new therapies targeting p53 for a prophylactic treatment of vascular diseases.
Key Words: angioplasty apoptosis balloon injury muscle, smooth atherosclerosis
| Introduction |
|---|
|
|
|---|
The tumor suppressor protein p53 has been postulated to play a critical role in both cell proliferation and apoptosis in many cell types.6 It was reported that p53 accumulates in VSMCs in human restenotic7 and atherosclerotic lesions.8 In vascular lesions, p53 was reported to be coexpressed with immediate-early gene products of human cytomegalovirus or MDM2, both of which are known to abolish p53 function.79 Thus, it was suggested that deregulated expression of p53 may play a role in the pathogenesis of human vascular diseases. This notion was supported by animal studies using local delivery of wild-type p53 gene10,11 or antisense p53 gene oligodeoxynucleotides12 into the arteries. However, untransfected bone marrowderived cells may potentially contribute to lesion formation.1315 Thus, the exact impact of p53 inactivation on vascular cell proliferation and apoptosis in vivo remains to be elucidated by genetic manipulation.
In this study, we used a new mouse model of acute vascular injury in p53+/+ and p53-/- mice. The endovascular injury induced marked enlargement of the artery with massive apoptosis of VSMCs, followed by luminal narrowing attributable to exuberant neointimal hyperplasia. There was no significant difference in the frequency of apoptosis. However, VSMC proliferation and the consequent neointimal hyperplasia were more prominent in p53-/- than in p53+/+ mice. Our findings provide genetic evidence that p53 may play an important role in controlling neointimal hyperplasia after mechanical vascular injury.
| Methods |
|---|
|
|
|---|
Mouse Femoral Injury Model
Surgery was carried out using a dissecting microscope (SMZ-800, Nikon). Transluminal mechanical injury of the femoral artery was induced by insertion of a large wire (0.38 mm in diameter, No. C-SF-15-15, COOK) as previously described.13,17,18 The mice were euthanized by intraperitoneal administration of an overdose of Nembutal at the time points indicated. At death, the mice were perfused with 0.9% NaCl solution followed by perfusion fixation with 4% paraformaldehyde in PBS (pH 7.4). The femoral artery was carefully excised, additionally fixed in 4% paraformaldehyde overnight at 4°C, and embedded in paraffin. Cross-sections (5 mm) were stained with H&E. Morphometric analysis was performed as described.17 A copy of the tutorial videotape of the surgical procedure will be sent by M.S. on request. The video can be viewed at http://plaza.umin.ac.jp/
msata.
Immunohistochemistry
Paraffin-embedded sections (5 µm) were deparaffinized, blocked with 1% goat serum, and incubated with an anti-mouse CD31 antibody (clone MEC13.3, PharMingen, San Diego, Calif), anti-p27 antibody (clone G173-524, PharMingen), and anti-p21 antibody (Santa Cruz Biotechnology, Santa Cruz, Calif). M.O.M. blocking system (Vector Laboratories) was used to block endogenous immunoglobulin with the anti-p27 mouse monoclonal antibody. Antibody distribution was visualized by the avidin-biotin complex technique and Vector Red substrate (Vector Laboratories). Smooth muscle cells were identified by immunostaining with an alkaline phosphataseconjugated monoclonal antibody to
-smooth muscle actin (clone 1A4, Sigma, St Louis, Mo). Sections were counterstained with hematoxylin.
TUNEL Staining
The sections (5 µm) were deparaffinized and treated with 20 µg/mL proteinase K for 30 minutes. Terminal deoxynucleotidyl transferase enzyme and fluorescein-dUTP were added to the tissue sections according to the instructions provided by the manufacturer (in situ death detection kit, Roche Molecular Biochemicals). Nuclei were counterstained with Hoechst 33258 (Sigma). The sections were mounted with ProLong Antifade Kit (Molecular Probes) and observed under a confocal microscope (FLUOVIEW FV300, Olympus).
Detection of Proliferating Cells by BrdU Incorporation
Proliferating cells were identified by incorporation of 5-bromo-2'-deoxyuridine (BrdU). Two weeks after the injury, BrdU Labeling Reagent (ZYMED) was administered intraperitoneally to p53+/+ and p53-/- mice at the dose of 1 mL per 100 g body weight. After 2 hours, the mice were euthanized and the femoral artery was perfusion-fixed with 10% neutral buffered formalin. Paraffin-embedded sections (5 mm) were stained with a biotinylated anti-BrdU antibody, streptavidin peroxidase, and 3,3'-diaminobenzidine according to the instructions provided by the manufacturer (BrdU Staining Kit, ZYMED).
Transmission Electron Microscopy
At 2 hours after surgery, the injured and uninjured arteries were perfusion-fixed with 2.5% glutaraldehyde and 2% paraformaldehyde in PBS. The arteries were postfixed in 1% osmium tetroxide and embedded in epoxy resin (Epon 812). Thin sections were stained with 3% uranyl acetate and examined under a transmission electron microscope (H-7000, Hitachi).
Culture of Bone Marrow Cells From p53+/+ and p53-/- Mice
Total bone marrow cells were isolated from p53+/+ or p53-/- mice as described,13 and 4x106 cells were cultured in a well of 24-well dish in Humedia-SG media (KURABO, Osaka) supplemented with 50 ng/mL PDGF-BB. At 18 days, cells were fixed in 4% paraformaldehyde. After incubation in 0.5% NP40, cells were stained with an alkaline phosphataseconjugated monoclonal antibody to
-smooth muscle actin (clone 1A4, Sigma) and Vector Red substrate (Vector Laboratories). The number of positive cells in a high-power field was counted.
Statistical Analysis
All data are presented as mean±SEM. Statistical comparisons were made with ANOVA followed by the Students Newman-Keuls test. A value of P<0.05 was considered to be significant.
| Results |
|---|
|
|
|---|
|
Accelerated Cellular Proliferation in p53-/- Mice
In this model, the dilated lumen gradually narrows because of neointimal hyperplasia.17 At 2 weeks after injury, proliferating cells were identified within the media and the small neointima formed on the luminal side of the internal elastic lamina as determined by BrdU incorporation into the DNA in S-phase (n=4 for each group) (Figure 2A). We found that the percentage of BrdU-positive cells in p53-/- lesions was significantly higher than that found in p53+/+ lesions in neointima (55.7±10.0 versus 30.0±13.1%) and media (40.4±8.2 versus 23.0±6.4%). TUNEL staining revealed apoptotic cell death in neointima and media (Table). The number of TUNEL-positive nuclei found in p53-/- neointima was less than that observed in p53+/+ lesion. To investigate the mechanism by which the lack of p53 leads to increased cellular proliferation, we investigated the expression of cyclin-dependent kinase inhibitors, which play a pivotal role in the regulation of cellular proliferation. Immunostaining of the injured arteries harvested at 2 weeks revealed that p21WAF1 (p21) was expressed in the growing neointima. The number of p21-positive cells in p53-/- mice was significantly less than that in p53+/+ mice in neointima (25.4±4.0% versus 8.3±2.4%) and media (23.6±5.2% versus 9.9±2.8%) (Figure 2B). We seldom detected p27 KIP1 (p27) expression in neointimal cells of p53+/+ and p53-/- mice (Figure 2C), whereas p27 expression was readily detected in endothelial cells and adventitial inflammatory cells. These results suggest that p53 functions to inhibit vascular cell proliferation in the injured artery, at least in part, through induction of the p21 gene.
|
|
Enhanced Lesion Formation in p53-/- Mice
In this vascular injury model, the neointima continues to grow until 3 weeks, after when no significant change in the size of the neointima is observed.17 Concentric neointimal hyperplasia developed in the injured arteries of p53+/+ and p53-/- mice (Figure 3A). Morphological analysis revealed that the lesion of p53-/- mice was significantly larger than that of wild-type mice (intima to media ratio, 2.9±0.2 versus 1.8±0.2). In both p53+/+ and p53-/- mice, the neointima was exclusively composed of
-smooth muscle actinpositive cells (Figure 3B). The luminal side was almost completely reendothelialized, as determined by immunostaining for CD31. Consistent with our previous report17 and studies performed using clinical specimens,20,21 we detected occasional apoptosis of the smooth muscle cells in the neointima and media of the lesions (Figure 3C). There was no significant difference in the frequency of apoptosis in p53+/+ and p53-/- lesions in neointima (2.6±1.2% versus 2.0±0.9%) or in media (8.2±4.2% versus 9.8±4.4%).
|
Enhanced Differentiation of p53-/- Bone Marrow Cells Into
-ActinPositive Cells
We recently reported that bone marrowderived cells significantly contribute to neointimal formation in mouse model of vascular injury.13 To study the potential impact of genetic ablation of p53 on bone marrowderived smooth muscle cells, we cultured bone marrow cells from p53+/+ or p53-/- mice. Bone marrow cells from p53-/- mice produced significantly more
-smooth muscle actinpositive cells than p53+/+ bone marrow cells did (23.0±4.1% versus 7.5±1.6%, P<0.05) (Figure 4).
|
| Discussion |
|---|
|
|
|---|
The cyclin-dependent kinase inhibitor p21WAF1 gene is transcriptionally activated by p53.6 Overexpression of p21 has been shown to inhibit VSMC proliferation in vitro and in vivo.25,26 In this study, the p53-/- mice displayed accelerated cellular proliferation 2 weeks after the vascular injury, which was correlated with reduced expression of p21. Thus, it is likely that p53 functions to inhibit cell proliferation, at least in part, through induction of the p21 gene.
Although it has been reported that VSMC apoptosis occurs in human vascular lesions20,21 and in animal models of angioplasty,19,27 the molecular mechanism of vascular cell apoptosis remains unknown28 and the role of smooth muscle cell apoptosis in vascular remodeling has been controversial.29,30 It was reported that immediate-early gene products of human cytomegalovirus inhibit VSMC apoptosis by antagonizing p53 function.9 p53 deficiency in bone marrowderived cells decreased the percentage of TUNEL-positive cells in the lesions.24 Thus, it has been assumed that p53 functions to promote VSMC apoptosis and to inhibit their accumulation in vascular lesions.9,11,31 In this study, we found that the occurrence of apoptosis decreased in p53-/- lesions when neointima was growing. Our results suggest that p53 inhibits VSMC accumulation through proapoptotic functions as well as through antiproliferative effects in our model of vascular injury.
We recently reported that bone marrowderived cells significantly contribute to neointimal formation in mouse model of vascular injury.13 When we cultured bone marrow cells from p53+/+ or p53-/- mice, we found that p53-/- bone marrow cells produced more
-smooth muscle actinpositive cells than p53+/+ bone marrow cells did. It may be plausible that p53 may play a role in mobilization, differentiation, and proliferation of bone marrowderived smooth muscle progenitor cells.
In conclusion, we found that loss of p53 function results in accelerated cell proliferation and enhanced lesion formation after mechanical vascular injury. Disruption of p53 may impart a proliferative advantage not only to tumor cells32 but also to untransformed smooth muscle cells in the vascular lesions. Our findings suggest a previously unappreciated role of p53 in pathological tissue remodeling and provide the basis for the development of gene therapy or pharmacotherapeutics targeting p53 for a prophylactic treatment of postangioplasty restenosis.
| Acknowledgments |
|---|
Received June 18, 2003; accepted July 17, 2003.
| References |
|---|
|
|
|---|
2. Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty: Restenosis Stent Study Group. N Engl J Med. 1998; 339: 16721678.
3. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991; 17: 433439.[Abstract]
4. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R, Rosenfield K, Isner JM. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997; 95: 19982002.
5. Kuntz RE, Baim DS. Prevention of coronary restenosis. Circulation. 2000; 101: 21302133.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88: 323331.[CrossRef][Medline] [Order article via Infotrieve]
7. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994; 265: 391394.
8. Ihling C, Haendeler J, Menzel G, Hess R, Fraedrich G, Schaefer H, Zeiher A. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol. 1998; 185: 303312.[CrossRef][Medline] [Order article via Infotrieve]
9. Tanaka K, Zou JP, Takeda K, Ferrans VJ, Sandford GR, Johnson TM, Finkel T, Epstein SE. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation. 1999; 99: 16561659.
10. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K, Sueishi K. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 1998; 82: 147156.
11. George SJ, Angelini GD, Capogrossi MC, Baker AH. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther. 2001; 8: 668676.[CrossRef][Medline] [Order article via Infotrieve]
12. Matsushita H, Morishita R, Aoki M, Tomita N, Taniyama Y, Nakagami H, Shimozato T, Higaki J, Kaneda Y, Ogihara T. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circulation. 2000; 101: 14471452.
13. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403409.[CrossRef][Medline] [Order article via Infotrieve]
14. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001; 7: 738741.[CrossRef][Medline] [Order article via Infotrieve]
15. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med. 2001; 7: 382383.[CrossRef][Medline] [Order article via Infotrieve]
16. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4: 17.[CrossRef][Medline] [Order article via Infotrieve]
17. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000; 32: 20972104.[CrossRef][Medline] [Order article via Infotrieve]
18. Sata M, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Nagai R. Acute and chronic smooth muscle cell apoptosis after mechanical vascular injury can occur independently of the Fas-death pathway. Arterioscler Thromb Vasc Biol. 2001; 21: 17331737.
19. Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells following balloon injury. Circulation. 1997; 95: 981987.
20. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995; 91: 27032711.
21. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995; 147: 267277.[Abstract]
22. Tabas I. p53 and atherosclerosis. Circ Res. 2001; 88: 747749.
23. Guevara N, Kim H, Antonova E, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999; 5: 335339.[CrossRef][Medline] [Order article via Infotrieve]
24. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ, Havekes LM. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res. 2001; 88: 780786.
25. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995; 96: 22602268.
26. Yang Z, Simari R, Perkins N, Sang H, Gordon D, Nabel G, Nabel E. Role of the p21cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A. 1996; 93: 79057910.
27. Pollman MJ, Hall JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Circ Res. 1999; 84: 113121.
28. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000; 87: 184188.
29. Geng Y-J, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 22002208.
30. Fukuo K, Nakahashi T, Nomura S, Hata S, Suhara T, Shimizu M, Tamatani M, Morimoto S, Kitamura Y, Ogihara T. Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Gerontology. 1997; 43: 3542.
31. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998; 282: 290293.
32. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 1993; 8: 24572467.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
T. Suzuki, D. Sawaki, K. Aizawa, Y. Munemasa, T. Matsumura, J. Ishida, and R. Nagai Kruppel-like Factor 5 Shows Proliferation-specific Roles in Vascular Remodeling, Direct Stimulation of Cell Growth, and Inhibition of Apoptosis J. Biol. Chem., April 3, 2009; 284(14): 9549 - 9557. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Yokoyama, S. Minamisawa, H. Quan, T. Akaike, M. Jin, K. Otsu, C. Ulucan, X. Wang, E. Baljinnyam, M. Takaoka, et al. Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1547 - H1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Sanz-Gonzalez, L. Barquin, I. Garcia-Cao, M. Roque, J. M. Gonzalez, J. J. Fuster, M. T. Castells, J. M. Flores, M. Serrano, and V. Andres Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis Cardiovasc Res, September 1, 2007; 75(4): 803 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tanaka, M. Sata, D. Fukuda, Y. Suematsu, N. Motomura, S. Takamoto, Y. Hirata, and R. Nagai Age-Associated Aortic Stenosis in Apolipoprotein E-Deficient Mice J. Am. Coll. Cardiol., July 5, 2005; 46(1): 134 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, X.-L. Niu, A. M. Pippen, B. H. Annex, and C. D. Kontos Adenovirus-Mediated Intraarterial Delivery of PTEN Inhibits Neointimal Hyperplasia Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 354 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Andres Unexpected Proatherogenic Properties of p21: Beyond Cell Cycle Control? Circulation, December 21, 2004; 110(25): 3749 - 3752. [Full Text] [PDF] |
||||
![]() |
M. Sata and R. Nagai Origin of Neointimal Cells in Autologous Vein Graft Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1147 - 1149. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |